Evaluation of Cytomegalovirus (CMV) T‐Cell Mediated Immunity in Children With CMV DNAemia After Allogeneic Hematopoietic Cell Transplantation
Transplant Infectious Disease · 2026
DOI: 10.1111/tid.70253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Varvara Probst und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Pediatrics, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Cytomegalovirus, Immunity, Cellular. Die Arbeit nennt 21 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Cytomegalovirus (CMV) is among the most common infectious complications following allogeneic hematopoietic cell transplantation (allo‐HCT). The CMV T‐cell immunity panel (CMV‐TCIP, Viracor) assesses CMV cell‐mediated immunity (CMV‐CMI); however, its utility among pediatric allo‐HCT recipients remains unknown.
Methods
A retrospective analysis (January 2020–January 2024) among pediatric (≤ 18 years) allo‐HCT recipients with CMV DNAemia and at least one CMV‐TCIP test was performed. A %CMV‐CD4 + or %CMV‐CD8 + IFN‐γ ≤ 0.2% was categorized as a poor response, whereas a result > 0.2% was classified as adequate. Clinically significant CMV infection (csCMVi) was defined as viral load (VL) ≥ 500 IU/mL. CMV‐TCIP results were compared to CMV VL and the development of csCMVi after allo‐HCT.
Results
Twenty‐seven CMV‐TCIP results from 10 allo‐HCT recipients were analyzed. The median age at transplant was 8.5 years (IQR 2.75–14.3), predominantly for hematologic malignancy (70%), and with high‐risk CMV serostatus (R+, 90%). At the time of CMV‐TCIP testing, subjects with a VL < 500 IU/mL had a higher %CMV‐CD4 + IFN‐γ compared to those with a VL ≥ 500 IU/mL (0.36 vs. 0.04, p = 0.02). Peak CMV VLs were lower in those with adequate CD4 + and CD8 + T‐cell responses than in those with poor CD4 + and CD8 + T‐cell responses. In those who received CMV viral‐specific T‐cells (CMV‐VST, n = 5), increased %CD4 + and %CD8 + IFN‐γ responses post‐infusion were observed with a concordant downward trend in VL.
Conclusions
Our results demonstrate that the development of CMV‐CMI (particularly CD4 + IFN‐γ > 0.2%) was observed with lower CMV VLs and may provide immunologic insights into pediatric allo‐HCT recipients receiving CMV‐VST.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Pediatrics, University of Florida, Gainesville, Florida, USA.
- Host Defense Program, Division of Infectious Diseases, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio, USA.
ORCID-Profile: Varvara Probst, Christopher P Ouellette, Eunkyung Song
Zitieren
APA
Probst, V., Ouellette, C. P., & Song, E. (2026). Evaluation of Cytomegalovirus (CMV) T‐Cell Mediated Immunity in Children With CMV DNAemia After Allogeneic Hematopoietic Cell Transplantation. Transplant Infectious Disease. https://doi.org/10.1111/tid.70253
Vancouver
Probst V, Ouellette CP, Song E. Evaluation of Cytomegalovirus (CMV) T‐Cell Mediated Immunity in Children With CMV DNAemia After Allogeneic Hematopoietic Cell Transplantation. Transplant Infectious Disease. 2026. doi:10.1111/tid.70253
BibTeX
@article{Probst2026,
author = {Probst, Varvara and Ouellette, Christopher P and Song, Eunkyung},
title = {Evaluation of Cytomegalovirus (CMV) T‐Cell Mediated Immunity in Children With CMV DNAemia After Allogeneic Hematopoietic Cell Transplantation},
journal = {Transplant Infectious Disease},
year = {2026},
doi = {10.1111/tid.70253}
}
EUVIMED